Mark L Tykocinski

6420172, Jul 16, 2002

Dec 31, 1992

07/997715

Mark L. Tykocinski - Shaker Heights OH
Joseph Ilan - Cleveland Heights OH

TIB Company, LLC - Pepper Pike OH

C12N 500

435375, 4353201, 435455, 424 932, 424 9321, 536 245

An immunogenic tumor cell, and method for its formation, which includes a tumor cell treated to have an altered intracellular level of a molecular factor compared to an untreated tumor cell.

6797489, Sep 28, 2004

Oct 29, 2002

10/169687

Mark L. Tykocinski - Merion Station PA
Gregory J. Riely - Cleveland Heights OH

TR Associates, L.L.C. - Merion Station PA

C12P 2106

435 691, 4353201, 435325, 4352523, 514 2, 530350

Novel fusion proteins comprising PP14 are disclosed. The fusion proteins retain the immunoregulatory function of native PP14, but offer significant advantages. Methods for using the fusion proteins, and sequence encoding the same in the treatment of immune system diseases and disorders are therefore also disclosed, as are methods for recombinant production of the present fusion proteins.

7435585, Oct 14, 2008

Jul 25, 2002

10/205524

Mark L. Tykocinski - Philadelphia PA, US
Guoxing Zheng - Philadelphia PA, US

University of Pennsylvania - Philadelphia PA

C12N 5/00
C12N 5/02
C12N 5/06
C12N 5/16

435325, 435326, 435328, 435329

Methods for transferring one or more proteins to a cell are disclosed. The protein or proteins to be transferred are in the form of a fusion protein, and contain at least one domain encoding for a protein or peptide having trans signaling and/or adhesion function. The fusion protein is transferred to a cell by binding to a lipidated protein, which has been incorporated into the cell membrane. In an additional aspect of the invention, methods of making fusion proteins having cis signaling capabilities, as well as the ability to bind with receptors on the cell's own surface, are provided. Fusion proteins incorporating GPI or a homing element, and a costimulator or inhibitor domain can also be directly transferred to the cell surface. Methods for using cells which have undergone protein transfer according to the present methods are also disclosed. This includes use in a cancer vaccine, use for treatment of cancer or autoimmune disease, and use in determining costimulator threshold levels.

7569663, Aug 4, 2009

Jan 3, 2001

10/169686

Mark L. Tykocinski - Merion Station PA, US

C07K 14/00
C07K 14/705
A61K 38/16

530350, 514 2, 514 12

Novel chimeric proteins are disclosed. The proteins comprise at least two portions. The first portion binds to a first cell and decreases the cell's ability to send a trans signal to a second cell; the second portion sends its own trans signal to the second cell. Methods for making and using these proteins in the treatment of cancer, viral infections, autoimmune and alloimmune diseases are also disclosed, as are pharmaceutical formulations comprising the novel chimeric proteins and genes. Either the proteins themselves or a genetic sequence encoding the protein can be administered. Other methods are also disclosed in which two molecular components result in decrement of a first trans signal from a first cell and the conferring of a second trans signal to a second cell.

8039437, Oct 18, 2011

Jun 30, 2009

12/494680

Mark L. Tykocinski - Merion Station PA, US
Marjaneh Razmara - Philadelphia PA, US

The Trustees of the University of Pennsylvania - Philadelphia PA

A61K 38/16
C07K 14/715
C07K 14/52
C12N 15/00

514 122, 514 189, 514 213, 514 212, 435 697, 530300, 530350, 530351

Fusion proteins which act on the TWEAK and TRAIL signaling axes are provided. The proteins are useful in the treatment or amelioration of autoimmune diseases, particularly multiple sclerosis, as well as other diseases such as alloimmune diseases and cancer.

8329657, Dec 11, 2012

Aug 11, 2011

13/208091

Mark L. Tykocinski - Merion Station PA, US
Marjaneh Razmara - Philadelphia PA, US

The Trustees of the University of Pennsylvania - Philadelphia PA

A61K 38/16
C07K 14/715
C07K 14/52
C07K 19/00

514 193, 514 122, 514 133, 514 189, 514 194, 514 196, 514 212, 435 697, 530300, 530350, 530351, 530402

Fusion proteins which act on the TWEAK and TRAIL signaling axes are provided. The proteins are useful in the treatment or amelioration of autoimmune diseases, particularly multiple sclerosis, as well as other diseases such as alloimmune diseases and cancer.

20020037583, Mar 28, 2002

Sep 20, 2001

09/957056

Mark Tykocinski - Merion Station PA, US
Aoshuang Chen - Wayne PA, US
Guoxing Zheng - Wayne PA, US

A61K048/00
A61K039/00
C12N005/08

435/325000, 424/277100, 424/093210

Methods for transferring one or more proteins to a cell are disclosed. The protein or proteins to be transferred are in the form of a fusion protein, and contain at least one domain encoding for a protein or peptide having trans signaling and/or adhesion function. The fusion protein is transferred to a cell by binding to a lipidated protein, which has been incorporated into the cell membrane. Methods for using cells which have undergone protein transfer according to the present methods are also disclosed. This includes use in a cancer vaccine, use for treatment of cancer or autoimmune disease, and use in determining costimulator threshold levels.

20040161806, Aug 19, 2004

Feb 10, 2004

10/775942

Mark Tykocinski - Merion Station PA, US
Aoshuang Chen - Wayne PA, US
Guoxing Zheng - Wayne PA, US

G01N033/567
G01N033/574

435/007210, 435/007230

Methods for transferring one or more proteins to a cell are disclosed. The protein or proteins to be transferred are in the form of a fusion protein, and contain at least one domain encoding for a protein or peptide having trans signaling and/or adhesion function. The fusion protein is transferred to a cell by binding to a lipidated protein, which has been incorporated into the cell membrane. Methods for using cells which have undergone protein transfer according to the present methods are also disclosed. This includes use in a cancer vaccine, use for treatment of cancer or autoimmune disease, and use in determining costimulator threshold levels.